WJ Anderson, PM Short, PA Williamson, A Manoharan, BJ Lipworth.; University of Dundee, Dundee, Scotland, UK

10.1136/thoraxjnl-2013-204457.313

Introduction and Objectives Chronic propranolol does not improve airway hyper-responsiveness (AHR) in persistent asthmatics taking medium dose inhaled corticosteroid (ICS), 440 g/day¹. We wished to assess for any putative corticosteroid-sparing effect of propranolol added to low dose ICS versus higher dose ICS, on histamine AHR.

Methods We conducted a randomised double-blind placebo-controlled crossover trial in mild-moderate persistent asthmatics. Patients were run-in for 2 weeks on hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP) 100 g/day. Patients were then randomised to either: propranolol 80mg/day plus HFA-BDP 100 g/day; or placebo plus HFA-BDP 400 g/day, each for 4 weeks. Propranolol was up-titrated to 80mg/day for the second 2 weeks of treatment. Patients received tiotropium 18 g/day during run-in and both treatments, which was subsequently discontinued 5 days prior to histamine challenge (primary outcome).

Results 16 patients completed, mean: age 38yr; FEV₁ 86.4%; Histamine PC₂₀ 1.39mg/ml; ICS 406 g/day. Histamine PC₂₀ remained unchanged adding propranolol to HFA-BDP100 compared to baseline (HFA-BDP100): 0.17 doubling dilution (dd) difference (95%CI -0.58–0.92), but there was a significant improvement with HFA-BDP400 compared to both baseline 1.05dd (95%CI 0.43–1.66), P = 0.02; and propranolol 0.88dd (95%CI 0.45–1.30), P = 0.006 (Figure 1a). Significant improvements from baseline were observed with HFA-BDP400 for exhaled nitric oxide, blood eosinophils (Figure 1b) and Asthma Quality of Life Questionnaire (AQLQ) symptom score (Figure 1c), but not with propranolol. Salbutamol recovery time post-challenge was partially blunted by propranolol (median prolongation 5min compared to both baseline and HFA-BDP400, P = 0.002). Domiciliary evening FEV₁ also fell with propranolol (mean reduction from baseline 0.22L [95%CI 0.10–0.34L], P = 0.012) while Asthma Control Questionnaire (ACQ) showed no significant changes with either treatment compared to baseline.

Conclusions In mild-moderate persistent asthmatics, propranolol produced no additive effects on top of low dose ICS, while further significant improvements in AHR and inflammation were seen with a higher dose of ICS. Propranolol attenuated salbutamol recovery and reduced evening FEV₁, but not ACQ or AQLQ.

REFERENCES

1. Short PM, Williamson PA, Anderson WJ, Lipworth BJ. Randomised placebo-controlled trial to evaluate chronic dosing effects of propranolol in asthma. *Am J Respir Crit Care Med* 2013;187:1308–1314.

Abstract P162 Figure 1 (A) Histamine provocative concentration causing 20% fall in FEV₁. Geometric means with 95% confidence intervals (CI). (B) Blood eosinophil count. Means with 95% CI. (C.) Asthma Quality of Life Questionnaire (AQLQ) symptom component score. Means with 95% CI. HFA = hydrofluoroalkane beclomethasone dipropionate. Base = post run-in baseline measurements. HFA100 = 100 g/day. HFA400 = 400 g/day. Prop = Propranolol 80mg/day.

P163 TIOtropium DECREASES THE RISK OF EXACERBATIONS IN PATIENTS WITH SYMPTOMATIC ASTHMA REGARDLESS OF BASELINE CHARACTERISTICS INCLUDING MARKERS OF ALLERGIC STATUS

¹DMG Halpin, ²ED Bateman, ³DP Tashkin, ⁴M Engel, ⁵R Dahl, ⁶P Paggiaro, ⁷E Beck, ⁸M Vandewalker, ⁹W Seibold, ⁹P Moroni-Zentgraf, ⁹H Schmidt, ¹⁰HAM Kerstjens, ¹Royal Devon & Exeter Hospital, Exeter, UK; ²University of Cape Town, Cape Town, South Africa; ³David Geffen School of Medicine, University of California, Los Angeles, California, USA; ⁴Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany; ⁵Institute for Clinical Medicine, Aarhus University, Aarhus, Denmark; ⁶Pulmonary Unit, University Hospital of Pisa, Pisa, Italy; ⁷Institut für Gesundheitsförderung, Rüdersdorf Brandenburg, Germany; ⁸Allergy and Asthma Consultants, Jefferson City, Missouri, USA; ⁹Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany; ¹⁰University of Groningen and the Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, and Groningen Research Institute for Asthma and COPD, Groningen, The Netherlands

10.1136/thoraxjnl-2013-204457.314

Rationale The addition of tiotropium provides bronchodilation and reduces exacerbations in patients with severe asthma (Kerstjens *et al.* NEJM 2012). Subgroup analyses were performed to determine whether this positive effect was limited to definable subgroups.

Methods Eligible patients: were aged 18–75 years; had a ≥5-year history of asthma; were diagnosed before the age of 40; scored ≥1.5 on Asthma Control Questionnaire 7; and were life-long non-smokers or ex-smokers (<10 pack-years) who quit smoking =1 year before study enrolment. Patients had experienced ≥1 exacerbation in the previous year. Time to first severe exacerbation from the pooled data after 48 weeks was one of three primary end points. Secondary end points included time to first episode of asthma worsening. Subgroup analyses of time to first severe exacerbation were performed in groups defined by baseline characteristics, including age, allergic status, smoking status and reversibility.

Results 912 patients were randomised: 456 received 5 g tiotropium via Respimat Soft Mist Inhaler and 456 received placebo once daily for 48 weeks. In the total study group, the time to first severe exacerbation was increased by the addition of tiotropium (risk reduction 21%; hazard ratio 0.79; p = 0.03). The time to first episode of asthma worsening was increased in the tiotropium group compared with placebo (risk reduction 31%; hazard ratio 0.69; p < 0.001). Subgroup analyses showed that neither the time to first severe exacerbation (Figure) nor the time to first episode of asthma worsening was dependent on baseline characteristics (no significant interactions).

Abstract P163 Figure. Analysis of the time to severe asthma exacerbation by subgroups defined at baseline.

Conclusions The increase in time to first severe exacerbation and first episode of asthma worsening found with the addition of tiotropium was not limited to specific subgroups of patients, including some characteristics that are usually found in patients with chronic obstructive pulmonary disease, such as former smoking, non-allergic status or minimal reversibility. Tiotropium seems effective across a broad spectrum of patients with severe persistent asthma who remain symptomatic and experience exacerbations despite the combination use of moderate- to high-dose inhaled corticosteroids plus long-acting beta agonists.

P164 USE OF BETA-AGONISTS PRIOR TO HOSPITAL ATTENDANCE FOR SEVERE EXACERBATIONS OF ASTHMA: INSIGHTS FROM A RANDOMISED CONTROLLED TRIAL USING ELECTRONIC MONITORING OF INHALER USE

¹M Patel, ²J Pilcher, ¹D Shaw, ³M Weatherall, ¹A Knox, ²R Beasley; ¹Division of Respiratory Medicine, University of Nottingham, Nottingham, UK; ²Medical Research Institute of New Zealand, Wellington, New Zealand; ³University of Otago, Wellington, New Zealand

10.1136/thoraxjnl-2013-204457.315

Introduction Observational studies have reported that the over-use of inhaled beta-agonists during severe asthma is a common feature associated with a fatal outcome. However, patterns of actual use of beta-agonists prior to hospital attendance for severe exacerbations are poorly understood.

Objectives We have recently reported that in 303 adult asthma patients randomised to receive either combination budesonide/formoterol metered dose inhaler (MDI) as part of a single maintenance and reliever therapy regimen ('SMART') or as fixed-dose maintenance treatment with salbutamol MDI for relief ('Standard'), overuse of beta-agonists without subsequent medical review occurred commonly in both groups. We now report on the use of beta-agonists by patients who attended hospital with a severe exacerbation of asthma. Our hypothesis was that extremely high beta-agonist doses would be used by patients in both groups and that inhaled corticosteroid (ICS) non-adherence may occur in the Standard group during severe asthma.

Methods Data on MDI use, as measured by electronic monitoring, were extracted for each patient for the 14 24-hour periods before the attendance time at hospital for a severe exacerbation.

Results Electronic data were available for 7/7 and 9/11 hospital attendances in the SMART and Standard groups respectively. The median (range) daily number of actuations 14 days before hospital attendance was 4 (2 to 12) budesonide/formoterol in SMART and 4 (0 to 26) salbutamol and 2 (0 to 8) budesonide/formoterol in Standard. This increased to 11 (6 to 39) budesonide/formoterol in SMART and 25 (3 to 86) salbutamol and 4 (0 to 39) budesonide/formoterol in Standard, in the 24-hours before attendance. The median (range) maximum daily number of actuations was 14 (9 to 63) budesonide/formoterol in SMART and 46 (6 to 95) salbutamol in Standard. Repeated days of no ICS use occurred in 3/9 patients in the Standard group, despite concomitant salbutamol overuse.

Conclusions Very high doses of beta-agonists are commonly self-administered by patients for prolonged periods prior to hospital presentation with severe asthma. The opportunity exists for clinical review and appropriate medical intervention during this period, which may reduce the risk of a life-threatening attack.

P165 THE RELIABILITY AND PERFORMANCE OF ELECTRONIC MONITORS OF INHALER USE IN A REAL WORLD ASTHMA CLINICAL TRIAL

¹M Patel, ²J Pilcher, ¹D Shaw, ³M Weatherall, ²R Beasley; ¹Division of Respiratory Medicine, University of Nottingham, Nottingham, UK; ²Medical Research Institute of New Zealand, Wellington, New Zealand; ³University of Otago, Wellington, New Zealand

10.1136/thoraxjnl-2013-204457.316

Introduction Electronic monitoring is one method to measure the use of inhaled therapy in asthma patients in clinical trials, though the reliability of these devices has been variable. Implementation of trial quality control processes and reporting on the performance of electronic monitors during patient use may help to better understand their utility and limitations. The Smartinhaler Tracker is an electronic monitor for metered dose inhalers (MDIs) that records the date, time and number of actuations to the nearest second.

Objectives In a recently completed 24-week real-world randomised controlled trial of 303 asthma patients at risk of severe exacerbations, Smartinhaler Tracker electronic monitors were used to measure actual use of budesonide/formoterol and salbutamol MDI therapy with two treatment regimens. Our aim is to report on the performance of these monitors, based on the implementation of extensive pre-trial and within-trial validation protocols for their use.

Methods Pre-study use checks involved two actuations of the MDI, with a further two actuations performed at least two hours later. Within-study monitor checks, performed prior to dispensing at follow-up clinic visits, included a computerised check of monitor clock function, actuation accuracy and battery life. Within-study data checks, performed after use of MDIs by participants during the trial, involved computerised checks of monitor clock function prior to data upload.

Results 2678/2728 (98.2%) monitors passed pre-study use checks; 46/50 monitors failed pre-study checks either because they did not record actuations that were performed, or erroneously recorded extra actuations. 76/2642 (2.9%) monitors dispensed to participants failed within-study monitor checks; 33/76 monitors failed because the battery was not fully charged. 51/2642 (1.9%) monitors failed data upload checks, mostly as a result of fluid immersion during participant use. 93/2642 (3.5%) monitors were lost or thrown away by participants. Complete data was available from 2498/2642 (94.5%) of dispensed monitors and 2498/2549 (98.0%) of returned monitors.

Conclusions The Smartinhaler Tracker is a reliable monitor for measuring MDI use in a real-world asthma clinical trial. Implementation of extensive monitor and data-checking protocols reduces data loss. The use of validated and reliable electronic monitors is the optimal method to assess patterns of inhaled medication use.

P166 EFFECTS OF LOW-VS HIGH-DOSE FLUTICASONE/FORMOTEROL COMBINATION THERAPY ON AMP CHALLENGE IN ASTHMATIC PATIENTS

¹F Kannies, ²Z Diamant, ³M Lomax, ³M Jain; ¹Practice for Allergy and Family Medicine, Reinfeld, Germany; ²Department of Respiratory Medicine and Allergology, Skane University Hospital, Lund, Sweden; ³Mundipharma Research Limited, Cambridge, UK

10.1136/thoraxjnl-2013-204457.317

Background The ICS fluticasone propionate (FP) and the LABA formoterol fumarate (FORM) have now been combined in a single aerosol inhaler (FP/FORM; *flutiform*). The effect of low- (2 puffs 50/5 g bid) vs high-dose (2 puffs 250/10 g bid) FP/FORM on airway responsiveness to AMP was compared in an